COX-2 inhibitors and type 4 error. - Wikidata - awgldk - TriplyDB

COX-2 inhibitors and type 4 error.

COX-2 inhibitors and type 4 error.

http://www.wikidata.org/entity/Q42905098

about

Coxibs and cardiovascular risk

P2860

Q28192582-9FEDB7DB-5AA5-4938-9BC0-A5BBC94E584A

P2860

COX-2 inhibitors and type 4 error.

http://www.wikidata.org/entity/Q42905098

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

COX-2 inhibitors and type 4 error.

@en

COX-2 inhibitors and type 4 error.

@nl

type

label

COX-2 inhibitors and type 4 error.

@en

COX-2 inhibitors and type 4 error.

@nl

prefLabel

COX-2 inhibitors and type 4 error.

@en

COX-2 inhibitors and type 4 error.

@nl

P1433

Q42905098-4CEDF56A-5759-402F-9364-58CA35970D3D

P1476

Q42905098-C3E6DC83-54E7-4695-991C-FBDCF14AEFF2

P2093

Q42905098-1A0C0B97-7576-4F78-8A90-693057AF6356

Q42905098-8C1B86F2-214D-43DB-B7C7-13434413C7C8

P2860

Q42905098-0A9B62F9-80C8-4F10-9542-8FBA70FA2808

Q42905098-100EC67F-AC22-491E-A21B-01C24284DE4A

Q42905098-172D5693-C013-4866-B5E9-CB5858A3CB66

Q42905098-253F7259-6BED-46D2-8998-C218F52CA499

Q42905098-25B1F741-ECDE-47A0-BF9F-216A68BF8DEE

Q42905098-264A717A-F880-4F16-99A0-84BEEBFB3EFA

Q42905098-3E1BAA8B-C630-4849-A93E-F8E1EA6BE1DD

Q42905098-619E5FD3-031F-4A33-B897-B2C554C2ED0C

Q42905098-67536947-0B8C-4996-9E9A-8D322EF11494

Q42905098-B2DF3F84-04BB-431C-ADA1-E8BD5EE873E5

P304

Q42905098-B868E09F-8CCC-4701-9835-4B4D6CF37B64

P31

Q42905098-A50D0594-ED04-4BBC-9840-65362F5BD3D8

P407

Q42905098-95E80760-CF02-4376-8BBA-2122F722C3BE

P433

Q42905098-53712BAC-5866-45C4-8DE0-F1177CB6BDA2

P478

Q42905098-6158AE84-4D64-4F61-8BCA-F20E9DCF34BA

P577

Q42905098-EB226A1B-54A9-4177-91A2-D534E3E839E4

P698

Q42905098-8EAE833C-06BF-4219-9668-32B3ED846E9C

P932

Q42905098-24CEDE4C-EDCC-4907-A88B-B08869079FB8

P1433

Canadian Medical Association Journal

P1476

COX-2 inhibitors and type 4 error

@en

P2093

Frantisek Gazdik

http://www.w3.org/2001/XMLSchema#string

Michal R Pijak

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

Aspirin use may change cost-effectiveness of COX-2 inhibitors

Risk of cardiovascular events associated with selective COX-2 inhibitors.

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

The double-edged sword of COX-2 selective NSAIDs

What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).

Seeking disclosure.

A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

Type 3 and type 4 errors in the statistical evaluation of clinical trials.

P304

190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

169

http://www.w3.org/2001/XMLSchema#string

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12900475

http://www.w3.org/2001/XMLSchema#string

P932

167118

http://www.w3.org/2001/XMLSchema#string